BioCentury | Aug 16, 2018
Distillery Therapeutics

Infectious disease

...in Phase I/II testing for HBV infection and preclinical testing for hepatocellular carcinoma (HCC). TARGET/MARKER/PATHWAY: Cyclophilin...
...doi:10.1021/acs.jmedchem.8b00802 CONTACT: Richard L. Mackman, Gilead Sciences Inc., Foster City, Calif. email: Richard.Mackman@gilead.com Claire Quang Gilead Sciences Inc. Cyclophilin...
BioCentury | Feb 2, 2018
Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

...NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that a cyclophilin D (CYPD) inhibitor from...
...Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF), Lund, Sweden Product: NVP025 Business: Musculoskeletal Indication: Treat mitochondrial myopathy Allison Johnson NVP025 Karolinska Institute NeuroVive Cyclophilin...
BioCentury | Jan 5, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

...Namenda XR memantine. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Ophthalmic Jaime De Leon Aczone Atrisone cyclosporine Dapsone topical gel Delzicol memantine mesalamine Namenda XR Restasis Allergan plc Cyclophilin...
BioCentury | Jan 4, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

...Delzicol mesalamine, topical acne treatment Aczone and Alzheimer disease drug Namenda XR memantine. Jaime De Leon cyclosporine Restasis Allergan plc Cyclophilin...
BioCentury | Jan 3, 2018
Company News

Allergan among companies unveiling price hikes

...2017) . Jaime De Leon ASP0456 Avonex BIIB017 Constella cyclosporine interferon beta-1a linaclotide Linzess natalizumab Peginterferon beta-1a Plegridy Restasis Tysabri Allergan plc Amgen Inc. Biogen Inc. Johnson & Johnson Merck & Co. Inc. Novo Nordisk A/S Sanofi Cyclophilin Guanylate...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

...NASDAQ:ALT) CD4 and CD8 T cell booster HepTcell (Ph I) 1 ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV) Cyclophilin...
BioCentury | Feb 15, 2017
Distillery Therapeutics

Neurology

...antagonist, in preclinical testing to treat hepatitis B viral (HBV) infection and HCV/HBV/HIV-1 co-infection. TARGET/MARKER/PATHWAY: Cyclophilin...
...Mario Negri Institute for Pharmacological Research, Milan, Italy email: valentina.bonetto@marionegri.it Hongjiang Li Mario Negri Institute for Pharmacological Research Cyclophilin...
BioCentury | Dec 1, 2016
Product R&D

De-stressing about NASH

...none of the programs are based on cyclophilin inhibitors. Hansson told BioCentury the company thought cyclophilin...
...exposure in the liver and very little cyclophilin binding in other organs, is a broad-spectrum cyclophilin...
...binding in other organs, is a broad-spectrum cyclophilin inhibitor acting on different family members, including cyclophilin...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Infectious disease

...animal models of viral infection. Scynexis Inc. and Waterstone Pharmaceuticals Ltd. have SCY-635 , a cyclophilin...
...Inc. has EDP-494 , a cyclophilin inhibitor, in Phase I testing to treat HCV. TARGET/MARKER/PATHWAY: cyclophilin...
...la Sante et de la Recherche Medicale (INSERM) University of Montpellier Cyclophilin A (CYPA) (PPIA) Cyclophilin B (CYPB) (PPIB) Cyclophilin...
BioCentury | Oct 31, 2016
Company News

NeuroVive, Arbutus Biopharma deal

...NeuroVive regained all rights to the product. Arbutus discontinued development of the orally available sangamide-based cyclophilin...
Items per page:
1 - 10 of 118